Neurology and Stroke Center, University Hospital Basel & University of Basel, Basel, Switzerland
Neurology and Stroke Center, University Hospital Basel & University of Basel, Basel, Switzerland.
J Neurol Neurosurg Psychiatry. 2022 Feb;93(2):119-125. doi: 10.1136/jnnp-2021-327236. Epub 2021 Oct 11.
The optimal timing to start direct oral anticoagulants (DOACs) after an acute ischaemic stroke (AIS) related to atrial fibrillation (AF) remains unclear. We aimed to compare early (≤5 days of AIS) versus late (>5 days of AIS) DOAC-start.
This is an individual patient data pooled analysis of eight prospective European and Japanese cohort studies. We included patients with AIS related to non-valvular AF where a DOAC was started within 30 days. Primary endpoints were 30-day rates of recurrent AIS and ICH.
A total of 2550 patients were included. DOACs were started early in 1362 (53%) patients, late in 1188 (47%). During 212 patient-years, 37 patients had a recurrent AIS (1.5%), 16 (43%) before a DOAC was started; 6 patients (0.2%) had an ICH, all after DOAC-start. In the early DOAC-start group, 23 patients (1.7%) suffered from a recurrent AIS, while 2 patients (0.1%) had an ICH. In the late DOAC-start group, 14 patients (1.2%) suffered from a recurrent AIS; 4 patients (0.3%) suffered from ICH. In the propensity score-adjusted comparison of late versus early DOAC-start groups, there was no statistically significant difference in the hazard of recurrent AIS (aHR=1.2, 95% CI 0.5 to 2.9, p=0.69), ICH (aHR=6.0, 95% CI 0.6 to 56.3, p=0.12) or any stroke.
Our results do not corroborate concerns that an early DOAC-start might excessively increase the risk of ICH. The sevenfold higher risk of recurrent AIS than ICH suggests that an early DOAC-start might be reasonable, supporting enrolment into randomised trials comparing an early versus late DOAC-start.
急性缺血性脑卒中(AIS)与心房颤动(AF)相关后开始直接口服抗凝剂(DOACs)的最佳时机仍不清楚。我们旨在比较早期(AIS 后≤5 天)与晚期(AIS 后>5 天)DOAC 启动。
这是对八项前瞻性欧洲和日本队列研究的个体患者数据汇总分析。我们纳入了 AIS 与非瓣膜性 AF 相关且在 30 天内开始使用 DOAC 的患者。主要终点是 30 天内复发性 AIS 和 ICH 的发生率。
共纳入 2550 例患者。1362 例(53%)患者早期开始使用 DOAC,1188 例(47%)患者晚期开始使用 DOAC。在 212 患者年中,37 例患者发生复发性 AIS(1.5%),16 例(43%)在开始使用 DOAC 之前;6 例(0.2%)发生 ICH,均在开始使用 DOAC 后。在早期 DOAC 开始组中,23 例(1.7%)患者发生复发性 AIS,2 例(0.1%)患者发生 ICH。在晚期 DOAC 开始组中,14 例(1.2%)患者发生复发性 AIS;4 例(0.3%)患者发生 ICH。在倾向评分调整的晚期与早期 DOAC 开始组比较中,复发性 AIS 的风险无统计学显著差异(aHR=1.2,95%CI 0.5 至 2.9,p=0.69),ICH(aHR=6.0,95%CI 0.6 至 56.3,p=0.12)或任何卒中。
我们的结果不支持早期 DOAC 开始可能会过度增加 ICH 风险的担忧。复发性 AIS 的风险是 ICH 的七倍,表明早期 DOAC 开始可能是合理的,支持将比较早期与晚期 DOAC 开始的随机试验纳入。